AUSTIN, Texas, Aug. 28, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has been invited to present at the 2012 Gateway Conference being held on September 6 at the W San Francisco Hotel.
Vermillion management is scheduled to present at 11:00 a.m. Pacific time, with one-on-one meetings held throughout the day. As the first FDA-cleared blood test for pre-surgical cancer diagnosis of ovarian tumors by using a unique multi-biomarker approach, management will discuss the company's progress in making OVA1® the standard of care in the diagnosis of ovarian cancer.
To schedule a one-on-one meeting, visit www.gateway-conference.com and click on the Register/Login tab. You may also email your request to firstname.lastname@example.org or call Ron Both at (949) 574-3860.
About the Gateway Conference
Gateway Conference is designed to provide a unique gateway between influential members of the investment community and a select group of compelling publicly-traded companies. Portfolio managers, research analysts and brokers from buy-side and sell-side institutions will have the opportunity to learn about more than 50 emerging growth companies across a broad range of industries, from technology, business services and digital media, to clean-tech, consumer/retail, life sciences and natural resources. For more information, go to www.gateway-conference.com.
The invitation-only conference is hosted by Liolios Group, one of the nation's top investor relations agencies, and sponsored by leading firms that service the financial community. For more information about Liolios Group, visit www.liolios.com.
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com.
Investor Relations Contact:
Scott Liolios or Ron Both
|SOURCE Vermillion, Inc.|
Copyright©2012 PR Newswire.
All rights reserved